Intravenous thrombolysis for acute ischemic stroke in Asia

References

• World Health Organization. The World Health Report 2003: shaping the future. World Health Organization, Geneva, Switzerland (2003).
   Google Scholar
• Bonita R, Mendis S, Truelsen T, Bogousslavsky J, Toole J, Yatsu F. The global stroke initiative. Lancet Neurol.3(7), 391–393 (2004).
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: global burden of disease study. Lancet349(9067), 1269–1276 (1997).
   PubMed Web of Science ®Google Scholar
• Fagan S, Morgenstern L, Pettita A et al. Cost–effectiveness of tissue plasminogen activator for acute ischemic stroke. Neurology50(4), 883–890 (1998).
   PubMed Web of Science ®Google Scholar
• Chambers M, Koch P, Hutton J. Development of a decision-analytic model of stroke care in the United States and Europe. Value Health5(2), 85–97 (2002).
   Google Scholar
• Samsa GP, Reutter RA, Parmigiani G et al. Performing cost–effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. J. Clin. Epidemiol.52(3), 259–271 (1999).
   PubMed Web of Science ®Google Scholar
• Demaerschalk BM, Yip TR. Economic benefit of increasing utilization of intravenous tissue plasminogen activator for acute ischemic stroke in the United States. Stroke36(11), 2500–2503 (2005).
   PubMed Web of Science ®Google Scholar
• Rha JH, Saver JL. The impact of re-canalization on ischemic stroke outcome: a meta-analysis. Stroke38(3), 967–973 (2007).
   PubMed Web of Science ®Google Scholar
• Thomassen L, Waje-Andreassen U, Naess H, Aarseth J, Russell D. Doppler ultrasound and clinical findings in patients with acute ischemic stroke treated with intravenous thrombolysis. Eur. J. Neurol.12(6), 462–465 (2005).
   PubMedGoogle Scholar
• Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N. Engl. J. Med.333(24), 1581–1587 (1995).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: the European Cooperative Acute Stroke Study (ECASS). JAMA274(13), 1017–1025 (1995).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet352(9136), 1245–1251 (1998).
   PubMed Web of Science ®Google Scholar
• Clark WM, Albers GW, Madden KP, Hamilton S. The rt-PA (alteplase) 0- to 6-hour acute stroke trial, part A (A0267g): results of a double blind, placebo-controlled, multicenter study. Stroke31(4), 811–816 (2000).
   PubMed Web of Science ®Google Scholar
• Clark WM, Wissman S, Albers GW, Jhamandas JH, Madden KP, Hamilton S. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset: the ATLANTIS study – a randomized controlled trial. JAMA282(21), 2019–2026 (1999).
   PubMed Web of Science ®Google Scholar
• Hacke W, Donnan G, Fieschi C et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS and NINDS rt-PA stroke trials. Lancet363(9411), 768–774 (2004).
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N. Engl. J. Med.359(13), 1317–1329 (2008).
   PubMed Web of Science ®Google Scholar
• Wahlgren N, Ahmed N, Da´valos A et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke Monitoring Study (SITS-MOST): an observational study. Lancet369(9558), 275–282 (2007).
   PubMed Web of Science ®Google Scholar
• Lees KR, Bluhmki E, von Kummer R et al. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet375(9727), 1695–1703 (2010).
   PubMed Web of Science ®Google Scholar
• Brott TG, Haley EC, Levy DE et al. Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes. Stroke23(5), 632–640 (1992).
   PubMed Web of Science ®Google Scholar
• Haley EC, Levy DE, Brott TG et al. Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes. Stroke23(5), 641–645 (1992).
   PubMed Web of Science ®Google Scholar
• Haley EC, Brott TG, Sheppard GL et al. Pilot randomized trial of tissue plasminogen activator in acute ischemic stroke. Stroke24(7), 1000–1004 (1993).
   PubMed Web of Science ®Google Scholar
• Khatri P, Broderick JP, Pancioli AM. Risk of thrombolysis-associated intracerebral hemorrhage: the need to compare apples with apples. Stroke36(6), 1109–1110 (2005).
   PubMedGoogle Scholar
• Ueshima S, Matsuo O. The differences in thrombolytic effects of administrated recombinant t-PA between Japanese and Caucasians. Thromb. Haemost.87(3), 544–546 (2002).
   PubMed Web of Science ®Google Scholar
• Iso H, Folson AR, Sato S et al. Plasma fibrinogen and its correlates in Japanese and US population samples. Arterioscler. Thromb.13(6), 783–790 (1993).
   PubMedGoogle Scholar
• Iso H, Folson AR, Koike KA et al. Antigens of tissue plasminogen activator and plasminogen activator inhibitor 1: correlates in nonsmoking Japanese and Caucasian men and women. Thromb. Haemost.70(3), 475–480 (1993).
   PubMed Web of Science ®Google Scholar
• Murata M. Genetic polymorphisms associated with thrombotic disorders in the Japanese population. Fibrinolysis Proteolysis14, 155–164 (2000).
   Google Scholar
• Mori E, Yoneda Y, Tabuchi M et al. Intravenous recombinant tissue plasminogen activator in acute carotid artery territory stroke. Neurology42(5), 976–982 (1992).
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Kikuchi H, Hayakawa H et al. Clinical efficacy and safety of intravenous tissue plasminogen activator in acute embolic stroke: a randomized, double-blind, dose-comparison study of duteplase. In: Thrombolytic Therapy in Acute Ischemic Stroke III. Yamaguchi T, Mori E, Minematsu K, del Zoppo GJ (Eds). Springer-Verlag, Tokyo, Japan, 223–229 (1995).
   Google Scholar
• Yamaguchi T, Mori E, Minematsu K et al. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT). Stroke37(7), 1810–1815 (2006).
   PubMed Web of Science ®Google Scholar
• Toyoda K, Koga M, Naganuma M et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients; general outcomes and prognostic factors from the SAMURAI register. Stroke40(11), 3591–3595 (2009).
   PubMed Web of Science ®Google Scholar
• Mori E, Minematsu K, Nakagawara J, Yamaguchi T, Sasaki M, Hirano T. Effects of 0.6 mg/kg intravenous alteplase on vascular and clinical outcomes in middle cerebral artery occlusion. Japan Alteplase Clinical Trial II (J-ACT II). Stroke41(3), 461–465 (2010).
   PubMed Web of Science ®Google Scholar
• Nakagawara J, Minematsu K, Okada Y et al. Thrombolysis with 0.6 mg/kg intravenous alteplase for acute ischemic stroke in routine clinical practice. The Japan post-Marketing Alteplase Registration Study (J-MARS). Stroke41(9), 1984–1989 (2010).
   PubMed Web of Science ®Google Scholar
• The IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the Interventional Management of Stroke study. Stroke35(4), 904–912 (2004).
   PubMed Web of Science ®Google Scholar
• Alexandrov AV. Ultrasound identification and lysis of clots. Stroke35(Suppl. 1), 2722–2725 (2004).
   PubMed Web of Science ®Google Scholar
• Huang P, Chen CH, Yang YH, Lin RT, Lin FC, Liu CK. Eligibility for recombinant tissue plasminogen activator in acute ischemic stroke: way to endeavor. Cerebrovasc. Dis.22(5–6), 423–428 (2006).
   PubMed Web of Science ®Google Scholar
• Suwanwela NC, Phanthumchinda K, Likitjaroen Y. Thrombolytic therapy in acute ischemic stroke in Asia: the first prospective evaluation. Clin. Neurol. Neurosurg.108(6), 549–552 (2006).
   PubMedGoogle Scholar
• Padma MV, Singh MB, Bhatia R et al. Hyperacute thrombolysis with IV rtPA of acute ischemic stroke: efficacy and safety profile of 54 patients at a tertiary referral center in a developing country. Neurol. India55(1), 46–49 (2007).
   PubMedGoogle Scholar
• Pandian JD, Sethi V, Dhillon R et al. Is intravenous thrombolysis feasible in a developing country?. Cerebrovasc. Dis.20(2), 134–136 (2005).
   PubMedGoogle Scholar
• Sharma VK, Tsivgoulis G, Tan JH, Ong BKC, Chan BPL, Teoh HL. Feasibility and safety of intravenous thrombolysis in multiethnic asian stroke patients in Singapore. J. Stroke Cerebrovasc. Dis.19(6), 424–430 (2010).
   PubMed Web of Science ®Google Scholar
• Poungvarin N. Stroke in the developing world. Lancet352(Suppl. 3), 19–22 (1998).
   Google Scholar
• Wang Y, Wu D, Zhao X et al. Hospital resources for urokinase/recombinant tissue-type plasminogen activator therapy for acute stroke in Beijing. Surg. Neurol.72(Suppl. 1), S2–S7 (2009).
   Google Scholar
• Pandian JD, Srikanth V, Read SJ, Thrift AG. Poverty and stroke in India: a time to act. Stroke38(11), 3063–3069 (2007).
   PubMed Web of Science ®Google Scholar
• Heeley E, Anderson CS, Huang Y et al. Role of health insurance in averting economic hardship in families following acute stroke in China. Stroke40(6), 2149–2156 (2009).
   PubMed Web of Science ®Google Scholar
• Adams HP Jr, Bendixen BH, Kappelle LJ et al. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. Trial of Org 10172 in Acute Stroke Treatment. Stroke24(1), 35–41 (1993).
   PubMed Web of Science ®Google Scholar
• Yoneda Y, Yamamoto S, Hara Y et al. Post-licensed 1-year experience of systemic thrombolysis with tissue plasminogen activator for ischemic stroke in a Japanese neuro-unit. Clin. Neurol. Neurosurg.109(7), 567–570 (2007).
   PubMedGoogle Scholar
• Minematsu K, Yamaguchi T, Omae T. Spectacular shrinking deficit: rapid recovery from a major hemispheric syndrome by migration of an embolus. Neurology42(1), 157–162 (1992).
   PubMedGoogle Scholar
• Sharma SR, Sharma N. Hyperacute thrombolysis with recombinant tissue plasminogen activator of acute ischemic stroke: feasibility and effectivity from an Indian perspective. Ann. Indian Acad. Neurol.11(4), 221–224 (2008).
   PubMed Web of Science ®Google Scholar
• Nguyen TH, Truong ATL, Ngo MB et al. Patients with thrombolysed stroke in Vietnam have an excellent outcome: results from the Vietnam thrombolysis registry. Eur. J. Neurol.17(9), 1188–1192 (2010).
   PubMed Web of Science ®Google Scholar
• Wasay M, Barohi H, Malik A, Yousuf A, Awan S, Kamal AK. Utilization and outcome of thrombolytic therapy for acute stroke in Pakistan. Neurol. Sci.31(2), 223–225 (2010).
   PubMedGoogle Scholar
• Hsu YC, Sung SF, Ong CT, Wu CS, Su YH. Intravenous thrombolytic therapy for acute ischemic stroke: the experience of a community hospital. Acta Neurol. Taiwan18(1), 14–20 (2009).
   PubMedGoogle Scholar
• Chao AC, Hsu HY, Chung CP et al. Outcomes of thrombolytic therapy for acute ischemic stroke in chinese patients. The Taiwan Thrombolytic Therapy for Acute Ischemic Stroke (TTT-AIS) Study. Stroke41(5), 885–890 (2010).
   PubMed Web of Science ®Google Scholar
• Lau AY, Soo YO, Graham CA et al. An expedited stroke triage pathway is the key to shortening the door-to-needle time in delivery of thrombolysis treatment. Hong Kong Med. J.16(6), 455–462 (2010).
   PubMedGoogle Scholar
• Boddu DB, Prasad RG, Bandaru VCSS et al. Predictors of major neurologic improvement after intravenous thrombolysis in acute ischemic stroke: a hospital based study from Hyderabad, India. Ann. Indian Acad. Neurol.58(3), 403–406 (2010).
   Google Scholar
• Zhou XY, Wanga SS, Collins ML, Davis SM, Yan B. Efficacy and safety of different doses of intravenous tissue plasminogen activator in Chinese patients with ischemic stroke. J. Clin. Neurosci.17(8), 988–992 (2010).
   PubMed Web of Science ®Google Scholar
• Muengtaweepongsa S, Dharmasaroja P, Kummark U. Outcomes of intravenous thrombolytic therapy for acute ischemic stroke with an integrated acute stroke referral network: initial experience of a community-based hospital in a developing country. J. Stroke Cerebrovasc. Dis. doi:10.1016/j.jstrokecerebrovasdis.2010.03.017 (2011) (Epub ahead of print).
   Google Scholar
• Salam KA, Ummer K, Pradeep Kumar VG, Noone ML, Laila A, Ragini J. Intravenous thrombolysis for acute ischemic stroke: the Malabar experience 2003 to 2008. J. Clin. Neurosci.16(10), 1276–1278 (2009).
   PubMed Web of Science ®Google Scholar